1. Miller A. M., Horiguchi N., Jeong W. I., Radaeva S., Gao B. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res. 2011, 35 (5), 787–793.
2. Higuchi H., Gores G. J.Mechanisms of liver injury: an overview. Curr Mol Med. 2003, 3 (6), 483–490.
3. Li D., Li W., Chen Y., Liu L., Ma D., Wang H., Zhang L., Zhao S., Peng Q. Anti-fi brotic role and mechanism of Periplaneta americana extracts in CCl4-induced hepatic fi brosis in rats. Acta Biochim Biophys Sin (Shanghai) 2018, 50 (5), 491–498.
4. Wan J., Benkdane M., Teixeira-Clerc F., Bonnafous S., Louvet A., Lafdil F., Pecker F., Tran A., Gual P., Mallat A., Lotersztajnv S., Pavoinev C. M2 Kupffer cells promote M1 Kupff er cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology 2014, 59 (1), 130–142.
5. Szuster-Ciesielska A., Plewka K., Daniluk J., Kandefer-Szerszeń M. Zinc supplementation attenuates ethanoland acetaldehyde-induced liver stellate cell activation by inhibiting reactive oxygen species (ROS) production and by infl uencing intracellular signaling. Biochem Pharmacol. 2009, 78 (3), 301–314.
6. Jeong W. I., Park O., Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fi brosis. Gastroenterology 2008, 134 (1), 248–258.
7. Lieber C. S., Weiss D. G., Paronetto F. Value of fi brosis markers for staging liver fi brosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008, 32 (6), 1031–1039.
8. Lykiardopoulos B., Hagström H., Fredrikson M., Ignatova S., Stål P., Hultcrantz R., Ekstedt M., Kechagias S. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One, 2016, 11 (12), e0167776.
9. Li J., Niu J. Z., Wang J. F., Li Y., Tao X. H. Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fi brosis rat model. World J Gastroenterol. 2005, 11 (41), 6483–6488.
10. Campbell S., Timms P. M., Maxwell P. R., Doherty E. M., Rahman M. Z., Lean M. E., Danesh B. J. Eff ect of alcohol withdrawal on liver transaminase levels and markers of liver fi brosis. J Gastroenterol Hepatol. 2001, 16 (11), 1254–1259.
11. Friedman S. L., Bansal M. B. Reversal of hepatic fi brosis – fact or fantasy? Hepatology 2006, 43 (2 Suppl 1), S82–88.
12. Suda T., Okawa O., Masaoka R., Gyotoku Y., Tokutomi N., Katayama Y., Tamano M. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World J Hepatol. 2017, 9 (1), 64–68.
13. Gudowska M., Cylwik B., Chrostek L. The role of serum hyaluronic acid determination in the diagnosis of liver fibrosis. Acta Biochim Pol. 2017, 64 (3), 451–457.
14. Nøjgaard C., Johansen J. S., Christensen E., Skovgaard L. T., Price P. A., Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol. 2003, 39 (2), 179–186.
15. Trocme C., Leroy V., Sturm N., Hilleret M. N., Bottari S., Morel F., Zarski J. P. Longitudinal evaluation of a fi brosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat. 2006, 13 (10), 643–651.